Toll Free: 1-888-928-9744

La Jolla Pharmaceutical Company - Product Pipeline Review - 2016

Published: Jun 22, 2016 | Pages: 39 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

La Jolla Pharmaceutical Company - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'La Jolla Pharmaceutical Company - Product Pipeline Review - 2016', provides an overview of the La Jolla Pharmaceutical Company's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by La Jolla Pharmaceutical Company, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of La Jolla Pharmaceutical Company
- The report provides overview of La Jolla Pharmaceutical Company including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses La Jolla Pharmaceutical Company's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features La Jolla Pharmaceutical Company's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate La Jolla Pharmaceutical Company's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for La Jolla Pharmaceutical Company
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding La Jolla Pharmaceutical Company's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 La Jolla Pharmaceutical Company Snapshot 5 La Jolla Pharmaceutical Company Overview 5 Key Information 5 Key Facts 5 La Jolla Pharmaceutical Company - Research and Development Overview 6 Key Therapeutic Areas 6 La Jolla Pharmaceutical Company - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 La Jolla Pharmaceutical Company - Pipeline Products Glance 11 La Jolla Pharmaceutical Company - Late Stage Pipeline Products 11 Phase III Products/Combination Treatment Modalities 11 La Jolla Pharmaceutical Company - Clinical Stage Pipeline Products 12 Phase I Products/Combination Treatment Modalities 12 La Jolla Pharmaceutical Company - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Discovery Products/Combination Treatment Modalities 14 La Jolla Pharmaceutical Company - Unknown Stage Pipeline Products 15 Unknown Products/Combination Treatment Modalities 15 La Jolla Pharmaceutical Company - Drug Profiles 16 LJPC-501 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 LJPC-401 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 LJPC-0712 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 LJPC-30Sa 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 LJPC-30Sb 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 LJPC-6417 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Drugs for Undisclosed Indications 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 La Jolla Pharmaceutical Company - Pipeline Analysis 26 La Jolla Pharmaceutical Company - Pipeline Products by Target 26 La Jolla Pharmaceutical Company - Pipeline Products by Route of Administration 27 La Jolla Pharmaceutical Company - Pipeline Products by Molecule Type 28 La Jolla Pharmaceutical Company - Pipeline Products by Mechanism of Action 29 La Jolla Pharmaceutical Company - Recent Pipeline Updates 30 La Jolla Pharmaceutical Company - Dormant Projects 33 La Jolla Pharmaceutical Company - Discontinued Pipeline Products 34 Discontinued Pipeline Product Profiles 34 GCS-100 34 LJPC-1010 34 La Jolla Pharmaceutical Company - Company Statement 35 La Jolla Pharmaceutical Company - Locations And Subsidiaries 37 Head Office 37 Other Locations & Subsidiaries 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 38 Disclaimer 39
List of Tables
La Jolla Pharmaceutical Company, Key Information 5 La Jolla Pharmaceutical Company, Key Facts 5 La Jolla Pharmaceutical Company - Pipeline by Indication, 2016 7 La Jolla Pharmaceutical Company - Pipeline by Stage of Development, 2016 9 La Jolla Pharmaceutical Company - Monotherapy Products in Pipeline, 2016 10 La Jolla Pharmaceutical Company - Phase III, 2016 11 La Jolla Pharmaceutical Company - Phase I, 2016 12 La Jolla Pharmaceutical Company - Preclinical, 2016 13 La Jolla Pharmaceutical Company - Discovery, 2016 14 La Jolla Pharmaceutical Company - Unknown, 2016 15 La Jolla Pharmaceutical Company - Pipeline by Target, 2016 26 La Jolla Pharmaceutical Company - Pipeline by Route of Administration, 2016 27 La Jolla Pharmaceutical Company - Pipeline by Molecule Type, 2016 28 La Jolla Pharmaceutical Company - Pipeline Products by Mechanism of Action, 2016 29 La Jolla Pharmaceutical Company - Recent Pipeline Updates, 2016 30 La Jolla Pharmaceutical Company - Dormant Developmental Projects,2016 33 La Jolla Pharmaceutical Company - Discontinued Pipeline Products, 2016 34 La Jolla Pharmaceutical Company, Subsidiaries 37


List of Figures
La Jolla Pharmaceutical Company - Pipeline by Top 10 Indication, 2016 7 La Jolla Pharmaceutical Company - Pipeline by Stage of Development, 2016 9 La Jolla Pharmaceutical Company - Monotherapy Products in Pipeline, 2016 10 La Jolla Pharmaceutical Company - Pipeline by Target, 2016 26 La Jolla Pharmaceutical Company - Pipeline by Route of Administration, 2016 27 La Jolla Pharmaceutical Company - Pipeline by Molecule Type, 2016 28 La Jolla Pharmaceutical Company - Pipeline Products by Mechanism of Action, 2016 29

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global agricultural films market size is anticipated to reach USD 10.5 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to raise agricultural productivity, in order to meet surplus demand by growing population i

Read More...

Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. Evolv

Read More...

Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to driv

Read More...

Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the marke

Read More...

Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to mo

Read More...
Choose License Type
Single User - US $1500
Multi User - US $3000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify